Differential effects of the CRF-R1 antagonist GSK876008 on fear-potentiated, light- and CRF-enhanced startle suggest preferential involvement in sustained vs phasic threat responses

Neuropsychopharmacology

Volumn 34, Issue 6, 2009, Pages 1533-1542

  Walker, David ^a   Yang, Yong ^a   Ratti, Emiliangelo ^b   Corsi, Mauro ^b   Trist, David ^b   Davis, Michael ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GSK   (Italy)

^c EMORY UNIVERSITY   (United States)

Author keywords

Amygdale; Anxiety; Bed nucleus of the stria terminalis; Corticotropin releasing factor; Fear; Startle

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GSK 876008; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIORAL RESEARCH; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEAR; FEMALE; FOOTSHOCK; MALE; NONHUMAN; PHOTOSTIMULATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STARTLE REFLEX; THREAT; VISUAL STIMULATION;

ANALYSIS OF VARIANCE; ANIMALS; CORTICOTROPIN-RELEASING HORMONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; FEMALE; LIGHT; MALE; METHYLCELLULOSE; PHOTIC STIMULATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STARTLE REACTION;

EID: 64949096111     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2008.210     Document Type: Article

References (48)

1. Behan DP, Khongsaly O, Liu XJ, Ling N, Goland R, Nasman B et al. (1996). Measurement of corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in human plasma by two-site enzyme-linked immunoabsorbant assay. J Clin Endocrinol Metab 81: 2579-2586.
2. Brown JS, Kalish HI, Farber IE (1951). Conditional fear as revealed by magnitude of startle response to an auditory stimulus. J Exp Psychol 41: 317-328.
3. Campeau S, Davis M (1995). Involvement of the central nucleus and basolateral complex of the amygdala in fear conditioning measured with fear-potentiated startle in rats trained concurrently with auditory and visual conditioned stimuli. J Neurosci 15: 2301-2311.
4. Collins DR, Pare D (1999). Reciprocal changes in the firing probability of lateral and central medial amygdala neurons. J Neurosci 19: 836-844.
5. Davis M, Schlesinger LS, Sorenson CA (1989). Temporal specificity of fear-conditioning: effects of different conditioned stimulus-unconditioned stimulus intervals on the fear-potentiated startle effect. J Exp Psychol Anim Behav Process 15: 295-310.
6. de Jongh R, Geyer MA, Olivier B, Groenink L (2005). The effects of sex and neonatal maternal separation on fear-potentiated and light-enhanced startle. Behav Brain Res 161: 190-196.
7. de Jongh R, Groenink L, van der Gugten J, Olivier B (2002). The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine. Psychopharmacology 159: 176-180.
8. de Jongh R, Groenink L, van der Gugten J, Olivier B (2003). Light-enhanced and fear-potentiated startle: temporal characteristics and effects of alpha-helical corticotropin-releasing hormone. Biol Psychiatry 54: 1041-1048.
9. Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF et al. (1999). The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology 140: 79-86.
10. Di Fabio R, St-Denis Y, Sabbatini FM, Andreotti D, Arban R, Bernasconi G et al. (in press). Synthesis and pharmacological characterization of novel drug-like corticotropin-releasing factor 1 antagonists. J Med Chem.
11. Dong H-W, Swanson LW (2004). Organization of axonal projections from the anterolateral area of the bed nucleus of the stria terminalis. J Comp Neurol 468: 277-298.
12. Dong HW, Petrovich GD, Watts AG, Swanson LW (2001). Basic organization of projections from the oval and fusiform nuclei of the bed nuclei of the stria terminalis in adult rat brain. J Comp Neurol 436: 430-455.
13. Erb S, Stewart J (1999). A role for the bed nucleus of the stria terminalis, but not the amygdala, in the effects of corticotropin-releasing factor on stress- induced reinstatement of cocaine seeking. J Neurosci 19: RC35.
14. Fendt M, Koch M, Schnitzler H-U (1997). Corticotropin-releasing factor in the caudal pontine reticular nucleus mediates the expression of fear-potentiated startle in the rat. Eur J Neurosci 9: 299-305.
15. Gewirtz JC, McNish KA, Davis M (1998). Lesions of the bed nucleus of the stria terminalis block sensitization of the acoustic startle reflex produced by repeated stress, but not fear-potentiated startle. Prog Neuro Psychopharmacol Biol Psychiatry 22: 625-648.
16. Hammack SE, Richey KJ, Watkins LR, Maier SF (2004). Chemical lesion of the bed nucleus of the stria terminalis blocks the behavioral consequences of uncontrollable stress. Behav Neurosc 118: 443-448.
17. Hikichi T, Akiyoshi J, Yamamoto Y, Tsutsumi T, Isogawa K, Nagayama H (2000). Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharma-copsychiatry 33: 189-193.
18. Huber D, Veinante P, Stoop R (2005). Vasopressin and oxytocin excite distinct neuronal populations in the central amygdala. Science 308: 245-248.
19. Jasnow AM, Banks MC, Owens EC, Huhman KL (1999). Differential effects of two corticotropin-releasing factor antagonists on conditioned defeat in male Syrian hamsters (Mesocri-cetus auratus). Brain Res 846: 122-128.
20. Jasnow AM, Davis M, Huhman KL (2004). Involvement of central amygdalar and bed nucleus of the stria terminalis corticotropin-releasing factor in behavioral responses to social defeat. Behav Neurosci 118: 1052-1061.
21. Kalin NH, Takahashi LK (1990). Fear-motivated behavior induced by prior shock experience is mediated by corticotropin-releasing hormone systems. Brain Res 509: 80-84.
22. Lee Y, Davis M (1997). Role of the hippocampus, bed nucleus of the stria terminalis and amygdala in the excitatory effect of corticotropin releasing hormone on the acoustic startle reflex. J Neurosci 17: 6434-6446.
23. Lee Y, Fitz S, Johnson PL, Shekhar A (2008). Repeated stimulation of CRF receptors in the BNST of rats selectively induces social but not panic-like anxiety. Neuro Psychopharmacology 33: 2586-2594.
24. Liang KC, Melia KR, Miserendino MJD, Falls WA, Campeau S, Davis M (1992). Corticotropin-releasing factor: long-lasting facilitation of the acoustic startle reflex. J Neurosci 12: 2303-2312.
25. Mansbach RS, Brooks EN, Chen YL (1997). Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323: 21-26.
26. Meloni EG, Jackson A, Gerety LP, Cohen BM, Carlezon Jr WA (2006). Role of the bed nucleus of the stria terminalis (BST) in the expression of conditioned fear. Ann NY Acad Sci 1071: 538-541.
27. Potter E, Sutton S, Donaldson C, Chen R, Perrin M, Lewis K et al. (1994). Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci USA 91: 8777-8781.
28. Resstel LB, Alves FH, Reis DG, Crestani CC, Correa FM, Guimaraes FS (2008). Anxiolytic-like effects induced by acute reversible inactivation of the bed nucleus of stria terminalis. Neuroscience 154: 869-876.
29. Risbrough VB, Geyer MA (2005). Anxiogenic treatments do not increase fear-potentiated startle in mice. Biol Psychiatry 57: 33-43.
30. Risbrough VB, Hauger RL, Pelleymounter MA, Geyer MA (2003). Role of corticotropin releasing factor (CRF) receptors 1 and 2 in CRF-potentiated acoustic startle in mice. Psychopharmacology (Berl) 170: 178-187.
31. Risbrough VB, Hauger RL, Roberts AL, Vale WW, Geyer MA (2004). Corticotropin-releasing factor receptors CRF1 and CRF2 exert both additive and opposing influences on defensive startle behavior. J Neurosci 24: 6545-6552.
32. Rosen JB, Hitchcock JM, Sananes CB, Miserendino MJD, Davis M (1991). A direct projection from the central nucleus of the amygdala to the acoustic startle pathway: anterograde and retrograde tracing studies. Behav Neurosci 105: 817-825.
33. Sahuque LL, Kullberg EF, McGeehan AJ, Kinder JR, Hicks MP, Blanton MG et al. (2006). Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacology 186: 122-132.
34. Sakanaka M, Shibasaki T, Lederis K (1986). Distribution and efferent projections of corticotropin-releasing factor-like im-munoreactivity in the rat amygdaloid complex. Brain Res 382: 213-238.
35. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M et al. (1996). CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93: 10477-10482.
36. Sullivan GM, Apergis J, Bush DE, Johnson LR, Hou M, Ledoux JE (2004). Lesions in the bed nucleus of the stria terminalis disrupt corticosterone and freezing responses elicited by a contextual but not by a specific cue-conditioned fear stimulus. Neuroscience 128: 7-14.
37. Sun N, Cassell MD (1993). Intrinsic GABAergic neurons in the rat central extended amygdala. J Comp Neurol 330: 381-404.
38. Swerdlow NR, Britton KT, Koob GF (1989). Potentiation of acoustic startle by corticotropin-releasing factor (CRF) and by fear are both reversed by alpha-helical CRF (9-41). Neuro Psychopharmacology 2: 285-292.
39. Toufexis D, Davis C, Hammond A, Davis M (2005). Sex differences in hormonal modulation of anxiety measured with light-enhanced startle: possible role for arginine vasopressin in the male. J Neurosci 25: 9010-9016.
40. Van Pett K, Viau V, Bittencourt JC, Chan RK, Li HY, Arias C et al. (2000). Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol 428: 191-212.
41. Waddell J, Morris RW, Bouton ME (2006). Effects of bed nucleus of the stria terminalis lesions on conditioned anxiety: aversive conditioning with long-duration conditional stimuli and reinstatement of extinguished fear. Behav Neurosci 120: 324-336.
42. Walker DL, Davis M (1997a). Anxiogenic effects of high illumination levels assessed with the acoustic startle paradigm. Biol Psychiatry 42: 461-471.
43. Walker DL, Davis M (1997b). Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in light-enhanced vs fear-potentiated startle. J Neurosci 17: 9375-9383.
44. Walker DL, Davis M (2002a). Light-enhanced startle: further pharmacological and behavioral characterization. Psychopharmacology 159: 304-310.
45. Walker DL, Davis M (2002b). Quantifying fear potentiated startle using absolute vs percent increase scoring methods: implications for the neurocircuitry of fear and anxiety. Psychopharmacology 164: 318-328.
46. Walker DL, Davis M (2008). Role of the extended amygdala in short-duration versus sustained fear: a tribute to Dr. Lennart Heimer. Brain Struct Funct 213: 29-42.
47. Walker DL, Toufexis DJ, Davis M (2003). Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 463: 199-216.
48. Wynn PC, Hauger RL, Holmes MC, Millan MA, Catt KJ, Aguilera G (1984). Brain and pituitary receptors for corticotropin releasing factor: localization and differential regulation after adrenalect-omy. Peptides 5: 1077-1084.